How to keep up with gene editing

I read a lot of gene editing news, because we make a free monthly roundup on it. It's a field with new editors, clinical results, delivery work and regulation arriving from different directions. This is what I've learned about keeping up with it without letting it take over your week.

I don't work in gene editing, so this guide is based on making the roundup and seeing what turns out to matter when you look back over a month.

The short answer: pick a small number of sources you trust, check them at a regular time, and save the original source with a note about why it matters. Most of this guide is about why that is harder in gene editing than it sounds, and the ways people usually go about it.

Why is gene editing hard to keep up with?

Gene editing news comes from several different places. A clinical result might appear in a research paper, an approval in a regulator's announcement, a delivery advance in a preclinical study, and a crop rule in legislation. Company deals, patents and trial news add another layer. Each source uses a different amount of detail and makes a different part of the story easy to miss.

Look at September's roundup. The FDA approved Ultragenyx's FAYUVI for MPS IIIA. Patient-derived blood stem cells reached up to 70% prime-editing efficiency for a GATA2 variant. Researchers made the compact CgCas12n editor about 60 times more efficient in mammalian cells. The EU now distinguishes two categories of new genomic techniques for crops, and Japan made implanting heritable genome-edited embryos a criminal offence.

Some stories need careful reading because the result depends heavily on the model and the follow-up. Base editing reached all PCSK9 alleles in a human-embryo study, but chromosome abnormalities, mosaic effects and embryo arrest were also reported. That is a safety study, not a treatment result, and the delivery method affected what happened.

How do people usually keep up?

Most people use some mix of these:

• Newsletters. Good for a regular selection of clinical, technical and regulatory news. The catch is that somebody else decides what deserves space, so a delivery result or agricultural rule may be outside its focus.
• Journal alerts and preprint feeds. The closest route to new methods and results. They're also noisy, and titles rarely tell you how many patients, what model or how long the follow-up involved.
• Podcasts. Easy to fit into a commute, and useful for hearing why a result matters. Less useful when you need the exact editing efficiency, delivery system or safety caveat in front of you.
• Conferences and meetings. Often the first place to hear trial updates and unpublished editor or delivery work. They happen occasionally, and early findings can change before the full result is available.
• Colleagues and communities. A good way to find the paper or regulatory document that matters to your particular programme. It depends on who happens to see something and has time to pass it on.

None of them covers the whole field, so most people end up with a patchwork.

What tends to work

• Keep the list short. Three or four sources you trust are better than fifteen you feel guilty about. If one hasn't given you anything useful in a month, drop it.
• Pick a time. Fifteen minutes on the same day each week works better than catching up whenever you can. Once a month, make a little more time for the papers and regulatory decisions that affect your work.
• Write one line when you save something. Say whether it matters because of the editor, delivery system, model, patient result or rule. A bare link rarely gets looked at again.
• Go back to the source for anything you'll act on. A summary can tell you that an editor worked. For the exact efficiency, off-target analysis, patient count or follow-up, read the original.

That's most of it. It takes discipline, especially when one month can include an approval, a stem-cell result, new compact editors and new rules for crops and heritable editing.

One more option

This is why I built Iris. You describe your work in your own words, something like "in vivo liver editing with LNP delivery and long-term safety", and every month it reads across the field and writes you a briefing on what changed for you, with every source linked so you can check anything yourself.

It's one option, and a good routine with a couple of newsletters works well too. If you'd like to see the general version first, our free monthly podcast, Keeping up with Gene Editing, takes about five minutes to cover the month's biggest stories. The written report and every source are there too. When you'd like a briefing built around your own work, you can set up your own briefing.

If you work in gene editing and think I've missed something, I'd like to hear about it: joe@irisbriefings.com.